PAHC

Over the past six months, Phibro Animal Health Corp.'s stock price has seen significant movement, with a rise of 35.51%. Key events impacting the stock include strong earnings reports and guidance, the Zoetis Medicated Feed Additive (MFA) Acquisition, credit facility expansion, regulatory headwinds in Brazil, and analyst ratings. The company reported strong fiscal Q2 2026 earnings, beating EPS expectations, and a robust Q3 fiscal 2026 with net sales increasing 10% to $383.5 million and adjusted EBITDA rising 11% to $60.8 million. The acquisition of the Zoetis MFA portfolio in October 2024 has been a significant growth driver. In late April, Phibro announced an expansion of its revolving credit facility from $310 million to $435 million. A regulatory development in Brazil affecting certain antimicrobial products was announced after the Q3 fiscal 2026 quarter end, contributing to a sharp stock decline. As of May 7, 2026, analysts have an average "Hold" rating on PAHC stock, with a mean 12-month target price of $42.40.